Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter. The clinical-stage...
In an update that endorses the potential benefits of Prescient Therapeutic’s (ASX:PTX) anti-cancer drug PTX-100,...
Prescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent safety in an...
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its...
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results...
The US Food and Drug Administration has assigned a fast track designation to a new...
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing...
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico...
Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news...
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.